Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Four states joined a federal lawsuit against CVS Pharmacy that claims the company caused state Medicaid programs to pay higher prices than non-Medicaid payers for prescription drugs. The states ...

NEW YORK — CVS ... obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these ...

He said the deal would reduce the price that Caremark’s employer clients paid for obesity drugs by 10% to 15% compared with the previous year. Advertising “CVS Caremark was able to do what ...

"Drug withdrawal requires careful treatment and observation. Using pharmacological interventions such as benzodiazepines with monitored vital signs (pulse, blood pressure, among others) can ...

People taking Eli Lilly’s obesity drug ... This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1.

The trial included 751 people from across the U.S. who were overweight or had obesity ... CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered ...

This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded. It's important to have a range of drugs ...